Swiss Nuclides develops copper-based radiopharmaceuticals using its proprietary CuTrace™ platform to create novel radionuclide PET tracers for precision diagnostics and targeted cancer treatment. This technology addresses the high misdiagnosis rates in cancer patients by providing accurate diagnostic and therapeutic options that improve safety and efficacy while reducing costs.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer diagnostics often lead to misdiagnosis, impacting patient survival rates and quality of life. Existing radiodiagnostics lack comprehensive coverage for diagnosis, staging, and follow-up across various tumor types. The use of different radiometals in diagnosis and treatment increases manufacturing complexity and costs.
Solution
Swiss Nuclides leverages its CuTrace™ platform to develop copper-based radiopharmaceuticals for precision diagnostics and targeted cancer therapy. The CuTrace™ platform enables the creation of novel radionuclide PET tracers designed to improve diagnostic accuracy and therapeutic efficacy. By combining copper radiometals with specific cancer-targeting molecules, Swiss Nuclides aims to deliver personalized therapy for cancer patients at every stage of their disease. This approach facilitates the rapid development of diagnostic and therapeutic programs with an improved safety profile and advantageous economics.
Target Audience
The primary target audience includes cancer patients, oncologists, and medical professionals seeking precise diagnostic and therapeutic options for various cancer types.
Features
- CuTrace™ platform for flexible development of radiotherapeutics based on companion diagnostics.
- Copper-based radiopharmaceuticals for improved accuracy in targeted cancer treatment.
- PET tracers for precision diagnostics.
- Streamlined production process.
- Broad distribution network.